exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275612 RNA Name: hsa-miR-423-5p RNA Type: miRNA Chromosome: chr17 Starnd: + Coordinate: Start Site(bp): 30117095 End Site(bp): 30117117 External Links: hsa-miR-423-5p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand DCAF7 chr17 63550477 63594279 + PGAM1 chr10 97426191 97433444 + MINK1 chr17 4833340 4898061 + PSME3 chr17 42824385 42843760 + LIMD2 chr17 63695888 63701172 - SYVN1 chr11 65121780 65134533 - KLC2 chr11 66257294 66267860 + MYBL2 chr20 43667019 43716495 + DLGAP4 chr20 36306336 36528637 + CAPN15 chr16 527712 554636 + MAPKBP1 chr15 41774434 41827855 + PAK2 chr3 196739857 196832647 + ACTN4 chr19 38647649 38731589 + C1QTNF6 chr22 37180166 37199385 - MAPK8IP2 chr22 50600793 50613981 + BCORL1 chrX 129981107 130058083 + FAM83H chr8 143723933 143738234 - WDR45B chr17 82614562 82648553 - CDCA7 chr2 173354820 173368997 + PRR12 chr19 49591182 49626439 + CHP1 chr15 41230839 41281887 + TNFAIP3 chr6 137867214 137883312 + IL2RB chr22 37125843 37175054 - RAB8A chr19 16111889 16134234 + HNRNPA2B1 chr7 26173057 26201529 - ATN1 chr12 6924463 6942321 + EIF5AL1 chr10 79512601 79516440 + IGF2BP1 chr17 48997385 49056145 + PPDPF chr20 63520765 63522206 + CTSD chr11 1752755 1764573 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001472 chr5 36953719 36976504 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.5 chr16 29808679 29812227 + AC016876.2 chr17 7581964 7584086 - AC021078.1 chr5 149494314 149504670 - AL356488.2 chr1 109100193 109100619 + H19 chr11 1995176 2001470 - KCNQ1OT1 chr11 2608328 2699994 - MIR663AHG chr20 26167817 26251546 - MIRLET7BHG chr22 46053869 46113928 + NEAT1 chr11 65422774 65445540 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.